Lipidor AB | MedPath

Lipidor's Phase III Psoriasis Trial Reaches Halfway Enrollment Mark, Results Expected in April

4 months ago

• Lipidor AB has announced that half of the patients have been randomized in its Phase III clinical study of AKP02G2 for mild to moderate psoriasis. • The study, involving 294 patients across 15 clinics, compares AKP02G2 to a market-leading psoriasis treatment. • Patient recruitment is expected to be completed in February, with topline results anticipated in April 2025. • The company's CEO, Ola Holmlund, noted that reaching the halfway mark is a significant milestone, with all clinics now actively recruiting.

Lipidor AB Initiates Phase III Trial of AKP02G2 for Psoriasis Treatment

8 months ago

• Lipidor AB has enrolled the first patient in its Phase III clinical trial evaluating AKP02G2, a topical spray for mild to moderate psoriasis. • AKP02G2 combines calcipotriol and betamethasone, utilizing Lipidor's AKVANO technology, aiming for efficacy comparable to Enstilar. • The Phase III study, managed by Cliantha, plans to enroll 294 patients to assess AKP02G2's effectiveness and patient-friendliness. • AKP02G2 seeks to provide a fast-drying, easy-to-use treatment option for psoriasis patients, potentially improving adherence and outcomes.